biotech / news / / Barchart
Shares of Pfizer Inc. (PFE) have underperformed the broader market over the past year.
Pfizer is targeting $600 million in manufacturing cost savings for 2025.
KEY POINTS
- The Pfizer/Valneva Lyme vaccine showed 73%-75% efficacy but missed its primary endpoint.
- Analyst consensus on Pfizer stock has become slightly more bullish over the past two months.
- Pfizer’s GLP-1 obesity drug PF-3944 is a key post-2028 growth bet.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →